This study is for patients that have been diagnosed with chronic lymphocytic leukemia (CLL). The investigational drugs in this study are ibrutinib, obinutuzumab and venetoclax. The purpose of this study is to compare the usual treatment of ibrutinib and obinutuzumab to a combination treatment of ibrutinib and obinutuzumab plus the study drug, venetoclax.
This study is for patients that have been diagnosed with Leukemia or Lymphoma. and have been treated on one of the following studies: Pediatric Oncology Group (POG) 9404, 9425, 9426, or Dana Farber Cancer Institute (DFCI) ALL Consortium 95-01. The purpose of this study is to look at the heart function of patients selected by change to get DRZ compared to the heart function of patients selected by chance not to get DRZ. In this study, they will also look at gender, age at cancer diagnosis, current age, dose of chemotherapy, and if chest radiation influences the risk of early heard damage. Participants in this clinical trial are expected to come to one clinic visit.
This study is for patients who have been diagnosed with a form of Acute Lymphoblastic Leukemia (ALL) called Philadelphia chromosome positive (Ph+) ALL. The purpose of this study is to compare disease free survival (DFS) of Standard Risk (SR) pediatric Ph+ ALL treated with continuous imatinib combined with either a high-risk COG ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. A drug called imatinib in combination with chemotherapy will be given. Participants can expect to be in this study for up to 2 years and their health followed for up to 10 years.
This study is for subjects who have been diagnosed with acute leukemia or myelodysplastic syndrome (MDS) and are a candidate for allogeneic hematopoietic stem cell transplant (HSCT). The study is being done to learn if adding defibrotide to the standard medicines for prevention of acute Graft-versus-Host Disease (aGvHD), which is called immunoprophylaxis, will help to prevent aGvHD better than using the usual immunoprophylaxis medicines alone. The investigational drug in this study is called Defibrotide. The duration of participation for each patient is approximately 6 months.
This study is for patients that have been diagnosed with High Risk B-Lymphoblastic Leukemia (HR B-ALL). The investigational drug in this study is Ruxolitinib. The purpose of this study is to find out if the study drug, ruxolitinib, in combination with standard HR B-ALL treatment is safe and effective in children, adolescents, and young adults with HR B-ALL. Participants can expect to be in this study for the treatment period of approximately 26 months (females) or 38 months (males) plus the post-treatment follow-up. Subjects are considered on study during the post-treatment follow-up period until the subject is deceased, lost to follow-up, or until the study is completed. Subjects in this study will be followed until all enrolled subjects have been followed for 3 years from Day 1 or are deceased or lost to follow-up.
This study is for patients that have been diagnosed with Acute Myeloid Leukemia (AML) and Down Sydnrome (DS). The purpose of this study is to find out if subjects with standard risk DS AML can be treated with less treatment and still have successful outcomes as well as to find out if subjects with high risk DS AML can be successfully treated with stronger chemotherapy. Participants can expect to be in this study for about 6 months.
This study is for patients that have been diagnosed with 1 of the following types of cancer : Chronic Lymphocytic Leukemia (CLL), Small-Cell Lymphocytic Lymphoma (SLL), or of Non-Hodgkin Lymphoma (NHL) of which there are 2 mains types: B-Cell NHL or T-Cell NHL. The investigational drug being studied is PRT062070; it is also called "cerdulatinib."The primary purpose of Phase 2a of this study is to assess safety and the activity of the study drug in patients who have CLL, SLL, or B-cell NHL, or T-cell NHL. You will take the study drug until you withdraw your agreement to continue to take part in this study, your cancer becomes worse, you have severe side effects, the research study ends, or you have completed dosing with the study drug and all follow-up study visits.
Patients in this study have been diagnosed with CLL or SLL and will be starting or have recently started treatment for CLL or SLL.
This observational study is research that aims to collect data over time on how a certain treatment is used and its effects, without any change to normal care. This means that routine clinical practice is followed. Any treatment given follows normal routine and is decided by you and your doctor. This study will not alter or interfere with the normal care patients receive in any way.
The purpose of this observational study is to build a registry that will provide information on regimens used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Sometimes CLL and SLL can return (relapse) after treatment, or get worse (progress) during a course of treatment. If this happens, a new treatment is needed. The registry will collect the following information from patients regular care medical records for review and study: patients medical history and medications, patients cancer treatment and side effects, the results of patients regular care laboratory tests, and the results of cancer care and treatment procedures performed as part of patients regular care. The registry study will also collect information on how out-of-pocket costs impact cancer care and treatment. The registry that will be built from information gathered from this study can help doctors decide what to do in situations when a new treatment is needed. Importantly, they can also gather information to help doctors learn which treatments are most effective in these situations.
This study is for patients who have been previously treated for Chronic Lymphocytic Leukemia (or CLL), and have at least one high-risk cytogenetic abnormality (17p deletion, 11q deletion and/or P53 gene mutation).
The study is being done to determine how effective the combination of an investigational drug (ublituximab) and another currently FDA approved drug ibrutinib (also referred to as Imbruvica®) is when given to patients without causing serious side effects.
This study is for adult male and female patients with previously untreated acute myeloid leukemia (AML). The purpose of this study is to compare the effects, good and/or bad of three drug combinations. The first combination is the standard treatment of daunorubicin plus AraC. The second combination is another standard treatment of idarubicin plus AraC. The third combination will add the drug vorinostat to the standard IA therapy. The study team wants to see if the study treatments will get rid of leukemia cells and keep them from coming back for patients who may benefit from stem cell transplant. They also want to find stem cell transplant donors for patients who might benefit from a transplant according to standard practice, beginning at the time patients register for the study. Participants will be asked to take induction treatment for 1-2 months. If a participant gets consolidation, it could take from 1-4 months. Participants may go on to transplant any time in the next year after he/she goes into remission. After participants are finished with the study treatment, the study doctor will ask them to visit the office for follow-up exams for at least 5 years from the time they go into remission.